EFUDIX

This brand name is authorized in Australia, Estonia, France, Ireland, Israel, Malta, Mexico, Netherlands, New Zealand, Poland, South Africa, Turkey, UK.

Active ingredients

The drug EFUDIX contains one active pharmaceutical ingredient (API):

1
UNII U3P01618RT - FLUOROURACIL
 

Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine – which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the “S” phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand. Fluorouracil is used for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

 
Read more about Fluorouracil

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 EFUDIX Cream MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
L01BC02 Fluorouracil L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 4222F
EE Ravimiamet 1162842
FR Base de données publique des médicaments 60627235
GB Medicines & Healthcare Products Regulatory Agency 111309, 196930, 375759, 375760
IE Health Products Regulatory Authority 64351, 64360
IL מִשְׂרַד הַבְּרִיאוּת 7198
MT Medicines Authority MA1507/00801, PI565/23403A
MX Comisión Federal para la Protección contra Riesgos Sanitarios 77246
NL Z-Index G-Standaard, PRK 2585
NZ Medicines and Medical Devices Safety Authority 1901
PL Rejestru Produktów Leczniczych 100021476
TR İlaç ve Tıbbi Cihaz Kurumu 8698856350350, 8698856350367
ZA Health Products Regulatory Authority D/13.8/122

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.